Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: COMBO Clear all
Completed Phase 3 Interventional

Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

NCT00219180
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease

NCT03618641
View directory record Official record
Conditions
Melanoma, Lymph Node Cancer
Interventions
CMP-001, Nivolumab
Drug · Biological
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients

NCT00219193
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 6, 2026, 10:18 AM EDT
Completed No phase listed Observational

Use of CoG by Patients With Diabetes Mellitus

NCT03840161
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
non-invasive tissue glucose prediction
Device
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Phase 1 Interventional Results available

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

NCT04306900
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
Combination Product
Lead sponsor
Trishula Therapeutics, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

NCT06972992
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC47 +Semaglutide, Placebo+Semaglutide
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 6, 2026, 10:18 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

NCT05318573
View directory record Official record
Conditions
Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Interventions
Pembrolizumab, FF-10832
Drug
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
23
States / cities
Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Not applicable Interventional

The Patterns of Activity and Cognition During Treatment (PACT) Study

NCT04562987
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer Female
Interventions
Physical Activity, Attentional Control
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
21 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Phase 3 Interventional

The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

NCT00442221
View directory record Official record
Conditions
Migraine Headaches
Interventions
Sumatriptan and Naproxen sodium
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2007 · Synced Sep 6, 2026, 10:18 AM EDT
Terminated Phase 1 Interventional

Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer

NCT04158349
View directory record Official record
Conditions
Colorectal Cancer, Appendiceal Cancer, Peritoneal Carcinoma
Interventions
Oxaliplatin, mFOLFIRI
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Sep 6, 2026, 10:18 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Lidocaine and Esmolol to Improve the Quality of Recovery

NCT01114997
View directory record Official record
Conditions
Pain, Constipation, Nausea, Vomiting
Interventions
Lidocaine, Esmolol, Lidocaine + Esmolol (Combo)
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 6, 2026, 10:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

RM1 Project 2 - tAN fMRI

NCT05487664
View directory record Official record
Conditions
Auricular Stimulation
Interventions
Transcutaneous Auricular Neruostimulation (tAN)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Early Phase 1 Interventional

A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm

NCT05555342
View directory record Official record
Conditions
Lung Tumor, Metastatic Cancer
Interventions
Irreversible electroporation (IRE) ablation, Radiation Therapy
Procedure · Radiation
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension

NCT00353912
View directory record Official record
Conditions
Hypertension
Interventions
valsartan + amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

NCT01644175
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 6, 2026, 10:18 AM EDT
Terminated Not applicable Interventional

A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

NCT03618979
View directory record Official record
Conditions
Low Back Pain
Interventions
PPP treatment, PRP treatment, PRP and PL Combo treatment
Biological
Lead sponsor
Regenexx, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Broomfield, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 6, 2026, 10:18 AM EDT
Terminated Phase 3 Interventional

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00662740
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol QD, Placebo, Salmeterol, Tiotropium/Salmeterol QD+ Salmeterol, Tiotropium (Spiriva®)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
20
States / cities
Boulder, Colorado • Wheat Ridge, Colorado • Winter Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 6, 2026, 10:18 AM EDT
Terminated Not applicable Interventional Results available

A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders

NCT04247100
View directory record Official record
Conditions
Functional Gastrointestinal Disorders, Vagus Nerve Autonomic Disorder, Irritable Bowel Syndrome, Nausea, Dyspepsia
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS), Sham Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
Gisela Grotewold Chelimsky
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

NCT00387517
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Lower Jaw Dental Injections

NCT01574807
View directory record Official record
Conditions
Pain
Interventions
mepivacaine + lidocaine followed by lidocaine +lidocaine, lidocaine + lidocaine followed by mepivacaine + lidocaine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 6, 2026, 10:18 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation

NCT07099638
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline (VAR), Nicotine lozenge (NRT), Smartphone intervention with adherence components (COMBO-A), Smartphone intervention without adherence components (COMBO-B), Telephone Counseling
Drug · Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 6, 2026, 10:18 AM EDT
No Longer Available No phase listed Expanded access

Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

NCT02204553
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 6, 2026, 10:18 AM EDT
Recruiting Phase 1 Interventional

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

NCT05753722
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
Interventions
PRTH-101, Pembrolizumab
Biological
Lead sponsor
Incendia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 6, 2026, 10:18 AM EDT
Completed Phase 1 Interventional

Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer

NCT00287911
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, topotecan hydrochloride, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 6, 2026, 10:18 AM EDT